Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Exclusion Criteria

• •planned intrathoracic, transplant, or central nervous system surgeries;
• •diagnostic-only procedures;
• •use of local/regional anesthesia (e.g., neuraxial/nerve blocks);
• •postoperative intensive care unit (ICU) transfer;
• •preoperative nasogastric/orogastric tube placement (from screening through 24 hours postoperatively)
• •nausea, vomiting, retching, or organic disease-related emesis (e.g., intestinal obstruction) within 24 hours preoperatively; history of malignancy, epilepsy, or vestibular dysfunction;
• •hypersensitivity to aprepitant;
• •recent use of aprepitant/NK1 antagonists (within 2 weeks prior to randomization), antiemetics (including 5-HT3 antagonists, corticosteroids; within 1 week), strong CYP3A4 inhibitors/substrates (within 1 week), CYP3A4 inducers (within 4 weeks), or warfarin (within 2 weeks);
• •clinically significant laboratory abnormalities (ALT/AST ≥2×upper limit of normal \[ULN\], total bilirubin ≥1.5×ULN, creatinine ≥1.5×ULN, hemoglobin ≤90 g/L)